Joint Formulary & PAD

Baricitinib - Atopic dermatitis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

PAD Profile

ChemicalSubstance :
Baricitinib
Indication :
Atopic dermatitis
Group Name :
Keywords :
Jak Inhibitor, Janus Kinase, dermatology, AD, immunomodulator
Brand Names Include :
Olumiant
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
4

Other Indications

Below are listed other indications that Baricitinib is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Atopic dermatitis.

Committee Recommendations (1)

The Surrey Heartlands integrated care system Area Prescribing Committee (APC) approve the use of baricitinib for the treatment of moderate to severe atopic dermatitis in line with NICE TA681. 

Baricitinib for this indication will be considered as RED on the traffic light status (treatment should be initiated and continued by specialist clinicians). 

Primary care prescriber should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.